|
RLF expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 4.02999855708686E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.48610013184225E-11 |
| Normal-vs-Stage2 |
1.58070223577056E-11 |
| Normal-vs-Stage3 |
2.12918571662613E-12 |
| Normal-vs-Stage4 |
2.02138306093502E-12 |
| Stage1-vs-Stage2 |
3.009800E-01 |
| Stage1-vs-Stage3 |
8.109900E-02 |
| Stage1-vs-Stage4 |
5.116200E-02 |
| Stage2-vs-Stage3 |
8.104000E-01 |
| Stage2-vs-Stage4 |
6.341800E-01 |
| Stage3-vs-Stage4 |
7.743000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
4.62030413928005E-12 |
| Normal-vs-AfricanAmerican |
2.77579999996558E-06 |
| Normal-vs-Asian |
2.0529999922303E-10 |
| Caucasian-vs-AfricanAmerican |
5.875200E-01 |
| Caucasian-vs-Asian |
7.134000E-01 |
| AfricanAmerican-vs-Asian |
8.128800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
3.47033513037331E-12 |
| Normal-vs-Female |
4.50706139076829E-12 |
| Male-vs-Female |
8.919200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
5.38680211548126E-11 |
| Normal-vs-Age(41-60Yrs) |
1.11044506923008E-12 |
| Normal-vs-Age(61-80Yrs) |
2.17814655201209E-12 |
| Normal-vs-Age(81-100Yrs) |
5.218800E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
7.647900E-02 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
4.403800E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
4.790800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
5.954800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
8.874800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.568400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.376000E-02 |
| Classical-VS-Follicular |
5.380100E-04 |
| Classical-VS-Other |
4.792000E-01 |
| Classical-VS-Normal |
2.82780021620965E-10 |
| Tall-VS-Follicular |
9.861800E-01 |
| Tall-VS-Other |
6.411600E-01 |
| Tall-VS-Normal |
7.31659177688471E-12 |
| Follicular-VS-Other |
6.655000E-01 |
| Follicular-VS-Normal |
3.1952218648712E-13 |
| Other-VS-Normal |
1.618260E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.39475106411646E-13 |
| Normal-vs-N1 |
2.19569917803142E-11 |
| N0-vs-N1 |
4.902200E-01 |
|
|
